Enterprise Value

5.136B

Cash

538.3M

Avg Qtr Burn

-11.69M

Short % of Float

13.79%

Insider Ownership

12.67%

Institutional Own.

94.87%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
VYJUVEKTM (B-VEC) (Topical Beremagene Geperpavec) Details
Skin disease/disorder, Dystrophic epidermolysis bullosa, Epidermolysis bullosa

Approved

Quarterly sales

Ophthalmic B-VEC Details
Dystrophic epidermolysis bullosa

Phase 1/2

Initiation

KB105 Details
Autosomal recessive congenital ichthyosis , Skin disease/disorder

Phase 1/2

Initiation

KB707 (IL-2 and IL-12) Details
Solid tumor/s, Multiple tumors, Cancer

Phase 1

Data readout

KB408 Details
Severe alpha-1 antitrypsin deficiency

Phase 1

Data readout

Phase 1

Data readout

Inhaled KB707 Details
Solid tumor/s, Lung Metastases, Cancer

Phase 1

Update

KB407 Details
Cystic fibrosis

Phase 1

Initiation